cosibelimab
cosibelimab is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including UNLOXCYT. Available dosage forms: injection, injection, solution, liquid.
Drug Details
- Generic Name
- cosibelimab
- Brand Names
- UNLOXCYT
- Application Number
- BLA761297
- Sponsor
- Samsung BioLogics Co. LTD
- NDC Codes
- 3
- Dosage Forms
- INJECTION, INJECTION, SOLUTION, LIQUID
- Routes
- INTRAVENOUS
- Active Ingredients
- COSIBELIMAB-IPDL, COSIBELIMAB
Indications and Usage
1. INDICATIONS AND USAGE UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. UNLOXCYT is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.